IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 140,765 shares of the company’s stock after selling 24,377 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 0.17% of IDEXX Laboratories worth $76,003,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Valley National Advisers Inc. boosted its stake in shares of IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after buying an additional 22 shares during the last quarter. Riverview Trust Co purchased a new position in shares of IDEXX Laboratories during the 1st quarter valued at approximately $26,000. DSM Capital Partners LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at approximately $33,000. Venturi Wealth Management LLC boosted its stake in shares of IDEXX Laboratories by 226.3% during the 4th quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock valued at $34,000 after buying an additional 43 shares during the last quarter. Finally, Private Wealth Management Group LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at approximately $34,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IDXX has been the subject of several research analyst reports. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research note on Monday, June 24th. Barclays reduced their price objective on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. Morgan Stanley reduced their price objective on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. Finally, William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $586.63.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded down $3.05 during trading hours on Wednesday, hitting $496.47. The company had a trading volume of 627,480 shares, compared to its average volume of 469,863. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. The business has a fifty day simple moving average of $501.03 and a 200-day simple moving average of $520.76. The firm has a market cap of $41.00 billion, a P/E ratio of 48.06, a price-to-earnings-growth ratio of 3.94 and a beta of 1.32.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.13. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The firm had revenue of $964.10 million for the quarter, compared to analyst estimates of $965.43 million. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.03 EPS for the current year.

Insider Activity

In other news, Director Bruce L. Claflin sold 200 shares of the firm’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $540.80, for a total transaction of $108,160.00. Following the transaction, the director now directly owns 161 shares of the company’s stock, valued at $87,068.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.